To determine the impact of ocrelizumab vs interferon (IFN) β-1a on cognition using the Symbol Digit Modalities Test (SDMT) in patients with relapsing multiple sclerosis (RMS) at increased risk of progressive disease, with or without baseline cognitive impairment.
No takes yet. Share an insight, caveat, or question.
Benedict et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: